Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2017-02-14 Interim / Quarterly Rep…
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2017
2017-02-14 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a Prospectus Supplement No. 4 filed pursuant to Rule 424(b)(3) and includes a Current Report on Form 8-K dated February 3, 2017. The content details a securities purchase agreement, convertible promissory notes, and related financing terms. The document is primarily about updates to the company's capital raising activities and financing arrangements, including issuance of convertible notes and related agreements. It is not an annual or quarterly report, audit report, or earnings release. It is not a proxy, governance, or legal proceeding document. The focus on securities purchase agreements and convertible notes indicates it is a Capital/Financing Update. The document length (15,000 characters) and detailed content confirm it is the actual filing, not just an announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-02-07 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Prospectus Supplement No. 4 filed pursuant to Rule 424(b)(3) and includes a Current Report on Form 8-K filed with the SEC. The content details a securities purchase agreement, convertible promissory notes, and related financing terms. It is a regulatory filing related to capital raising and financing activities, specifically describing the issuance of convertible notes and the terms of the securities purchase agreement. The document is not an annual or quarterly report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. The primary focus is on financing and capital structure update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2017-02-07 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement involving convertible promissory notes and related financing terms. It includes detailed information about the securities purchase agreement and the notes issued, which are financing activities. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document focuses on a financing transaction and related obligations, which fits the category of Capital/Financing Update. The document length is over 6,000 characters and contains substantive details about the financing arrangement, not just an announcement of a report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-02-03 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Prospectus Supplement No. 3 filed pursuant to Rule 424(b)(3) and includes a Current Report on Form 8-K as an annex. The content details securities purchase agreements, convertible promissory notes, termination of financing agreements, and unregistered sales of equity securities. The document is primarily a disclosure of financing activities and securities issuance rather than a full financial report or earnings release. It is not an annual or interim report, nor a call transcript or AGM material. The focus on securities purchase agreements, promissory notes, and financing arrangements aligns with capital or financing updates. Therefore, the document fits best under the category Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is a full filing rather than a brief announcement. Confidence is high given the clear focus on financing agreements and securities issuance.
2017-01-06 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Prospectus Supplement (Form 424B3) filed by Propanc Health Group Corporation. It serves to update a previous prospectus by incorporating a Form 8-K (Current Report) filed on December 30, 2016, which details new financing agreements and debt obligations. Since the document is a regulatory filing used to update registration statements and includes the text of a Form 8-K, it falls under the category of Regulatory Filings.
2017-01-06 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.